COGNITION THERAPEUTICS

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 Oct 2024 15:15:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 Oct 2024 11:55:00 By Nasdaq GlobeNewswire

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 Oct 2024 06:30:27 By Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 Aug 2024 06:31:24 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

08 Aug 2024 06:00:53 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

05 Aug 2024 06:30:19 By Nasdaq GlobeNewswire

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

29 Jul 2024 06:00:33 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

26 Jul 2024 15:11:52 By Nasdaq GlobeNewswire

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

02 Jul 2024 06:30:38 By Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

21 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

07 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

29 Apr 2024 06:30:57 By Nasdaq GlobeNewswire

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

22 Apr 2024 06:30:22 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

02 Apr 2024 06:30:47 By Nasdaq GlobeNewswire

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

01 Apr 2024 06:30:39 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

26 Mar 2024 06:00:56 By Nasdaq GlobeNewswire